Pharma Focus Asia

Fujifilm Invests US$83m to Expand Biotechnologies Microbial Capacity in UK


FUJIFILM Corporation plans to invest US$83 million dollars to expand microbial production capacity of FUJIFILM Diosynth Biotechnologies (FDB).


The new site will be located at United Kingdom and scheduled to begin its operations after 2022.

The building consists of new production line fully equipped with 2 X 2000L fermenters and a modular purification suite allowing FDB to meet the growing demand of microbial expressed therapies and also to develop antibodies and gene therapies.

The facility is not only meant to upgrade high volume production, also triple the FDB’s current capacity of microbial production at the United Kingdom site.

With this expansion, Fujifilm desired to achieve sales of 100 billion yen in the Bio CDMO business by ensuring the commitment of offering different types of therapies named recombinant proteins, antibodies, hormones, viral vectors and providing vaccines for customers with high quality products to grant unmet medical needs in healthcare sector.

The company expects that the increased microbial production capacitywill be ready after 2022.


NameFUJIFILM Diosynth Biotechnologies (FDB)
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?